Resapp Health Ltd. Stock Analysis RAP.AX

ResApp Health Ltd. engages in the research and commercial development of ResApp technology for the purpose of providing health care solutions for respiratory disease. The company is headquartered in Brisbane, Queensland. The company went IPO on 2005-01-12. The firm provides point of care diagnostic solutions for telehealth that are integrated into existing platforms. The firm is focused on developing apps to provide instant clinical diagnostic tests and management tools directly to consumers and healthcare providers. The Company’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. Its products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Its obstructive sleep aponia screening test uses overnight breathing and snoring sounds recorded on a smartphone.